Patents Issued in July 30, 2020
  • Publication number: 20200239832
    Abstract: The present invention relates to the production of o-aminobenzoic acid from fermentable substrates using microbial cells and alkali-containing bases during fermentation
    Type: Application
    Filed: October 12, 2018
    Publication date: July 30, 2020
    Inventors: Gernot JÄGER, Wolf KLOECKNER, Swantje BEHNKEN, Simon KLAFFL, Jamaleddine SASSI
  • Publication number: 20200239833
    Abstract: Methods of using magnetic display cells to replace secondary antibodies and magnetic beads in any cell manipulation methods. Cells displaying ligands for target cells are magnetized, and then used to bind the target cells. The complex can then be collected in a magnetic field, and thereby manipulated according to the application needs.
    Type: Application
    Filed: August 1, 2018
    Publication date: July 30, 2020
    Inventor: Glauco SOUZA
  • Publication number: 20200239834
    Abstract: Provided is a large-scale cell culture system for producing products without harming animals. Also provided is a method for making meat products using this cell culture system. Further provided is a method for making personal care products using this cell culture system, as well as a method for making nutritional supplements using this cell culture system.
    Type: Application
    Filed: April 16, 2020
    Publication date: July 30, 2020
    Inventors: Gabor FORGACS, Niyati GUPTA
  • Publication number: 20200239835
    Abstract: A method for isolating and/or culturing cambium stem cells of panax ginseng is disclosed. The method comprises a step of treating tissues containing panax ginseng cambium with a compound of formula I. The present application further relates to cambium stem cells of panax ginseng obtained according to the method and use of such cambium stem cells in preparing a product for a suspension culture of panax ginseng. The method for isolating and/or culturing cambium stem cells of panax ginseng according to the present application can effectively separate the cambium stem cells of the panax ginseng which have unlimited cytodieresis ability and strong anti-adversity ability, can provide a basis for ultra-large volume liquid culture, which can significantly reduce production costs.
    Type: Application
    Filed: March 8, 2019
    Publication date: July 30, 2020
    Inventors: Dong Wu, Chensheng Dai, Lili Cheng, Huaide Chen, Minxian Liu, Lili Hou, Zhuohe Jiang, Yujia Liu, Yuanjian Ling
  • Publication number: 20200239836
    Abstract: Biological products are disclosed that have improved qualities relative to those that are currently available. Disclosed are compositions and methods for modulating cellular physiology and pathological processing using compositions that are derived from various placenta/villous chorion tissue.
    Type: Application
    Filed: March 14, 2017
    Publication date: July 30, 2020
    Inventor: Scott A. Washburn
  • Publication number: 20200239837
    Abstract: Genetically modified mice are provided that express human ? variable (hV?) sequences, including mice that express hV? sequences from an endogenous mouse ? light chain locus, mice that express hV? sequences from an endogenous mouse ? light chain locus, and mice that express hV? sequences from a transgene or an episome wherein the hV? sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human ? variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human ? variable sequences, including human antibodies, are provided.
    Type: Application
    Filed: February 12, 2020
    Publication date: July 30, 2020
    Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Andrew J. Murphy, Karolina A. Meagher
  • Publication number: 20200239838
    Abstract: The invention provides a method of differentiating human pluripotent stem cells to ectodermal cell by treating human pluripotent stem cells, which are dissociated single cells, and inducing differentiation to ectodermal cells under conditions where a ROCK (Rho-kinase) inhibitor is present in a culture medium in contact with the cells after dissociation of the human pluripotent stem cells.
    Type: Application
    Filed: April 17, 2020
    Publication date: July 30, 2020
    Applicant: RIKEN
    Inventors: Yoshiki Sasai (deceased), Kiichi Watanabe
  • Publication number: 20200239839
    Abstract: The present invention provides a product comprising plated human hepatocytes on a surface and at least some of the plated hepatocytes are in one or more hepatocyte clusters on feeder cells, which are attached to the surface. A method of preparing plated human hepatocytes is also provided. The preparation method comprises applying human hepatocytes to a surface in the presence of feeder cells, co-culturing the applied hepatocytes with the feeder cells, and forming one or more hepatocyte clusters by the co-cultured hepatocytes on the feeder cells, which are attached to the surface. The plated hepatocytes may be used for various purposes, including the preparation of a hepatitis B virus (HBV) infected hepatocyte culture model and drug testing.
    Type: Application
    Filed: September 22, 2018
    Publication date: July 30, 2020
    Applicant: LifeNet Health
    Inventors: Jung Bok LEE, Angela Murchison, Edward LeCluyse, Jingsong Chen
  • Publication number: 20200239840
    Abstract: The present invention relates to methods for reprogramming a somatic cell to pluripotency by administering into the somatic cell at least one or a plurality of potency-determining factors. The invention also relates to pluripotent cell populations obtained using a reprogramming method.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 30, 2020
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: James A. Thomson, Junying Yu
  • Publication number: 20200239841
    Abstract: The present disclosure relates to methods and compositions for generating topographically organized tissues in vitro, for the resulting cultured tissue and components thereof, and for uses of such cultured tissue and its components in drug discovery, toxicology studies, and therapy.
    Type: Application
    Filed: January 27, 2020
    Publication date: July 30, 2020
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Lorenz Studer, Gustav Cederquist
  • Publication number: 20200239842
    Abstract: Preparation and expansion methods for human pluripotent stem cell-derived human retinal pigment epithelial cells are provided. The preparation method includes the following steps: collecting 3D-PRE spheroids derived from human pluripotent stem cells, performing mechanical separation to remove non-RPE cells and clusters which are non-pigmented and retain a pigmented RPE cell sheet, enzymatically digesting the pigmented RPE cell sheet to obtain an RPE single cell suspension, and thereby the human pluripotent stem cell-derived human retinal pigment epithelial cells are obtained. The expansion method includes centrifuging the RPE single cell suspension and removing a supernatant, resuspending in an RPE cell medium and seeding into a cell culture container precoated with extracellular matrix to allow primary culture, and subculturing the cells after cells spread out.
    Type: Application
    Filed: April 28, 2018
    Publication date: July 30, 2020
    Applicant: ZHONGSHAN OPHTHALMIC CENTER, SUN YAT-SEN UNIVERSITY
    Inventors: Xiufeng ZHONG, Jian GE, Shengxu LIU, Fuhua PENG
  • Publication number: 20200239843
    Abstract: The present invention is in the field of the cultivation of biological cells and tissues with organ-like function on a microphysiological scale and provides a method for the microphysiological co-cultivation of 3D organoid tissue and at least one 2D cell layer.
    Type: Application
    Filed: October 1, 2018
    Publication date: July 30, 2020
    Applicants: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V., EBERHARD KARLS UNIVERSITÄT TÜBINGEN
    Inventors: Peter LOSKILL, Christopher PROBST, Stefan LIEBAU, Kevin ACHBERGER, Jasmin HADERSPECK
  • Publication number: 20200239844
    Abstract: Disclosed herein are various embodiments relating to methods of producing iMGLs, for example, from pluripoteiit stem cells (PSCs), methods of using iMGLs, and compositions of iMGLs. Also disclosed herein are methods to study various neurological disorders, such as for studying Alzheimer's disease. In addition, disclosed herein are methods of investigating genotypic and phenotypic effects of microglia cells in various physiological and pathological environments in the CNS and brain.
    Type: Application
    Filed: February 26, 2018
    Publication date: July 30, 2020
    Inventors: Mathew BLURTON-JONES, Edsel ABUD, Wayne POON
  • Publication number: 20200239845
    Abstract: The present invention relates to expanded NK cells. The NK cells have been expanded ex vivo, are activated and have a cytotoxic phenotype. The cytotoxicity against malignant cells is markedly increased compared to non-expanded NK cells. The invention also relates to a method of treatment.
    Type: Application
    Filed: April 14, 2020
    Publication date: July 30, 2020
    Inventors: Sirac DILBER, Evren ALICI
  • Publication number: 20200239846
    Abstract: A process for the preparation of chondrocyte cell suspension and its use in defect site of knee or ankle or shoulder or wrist or elbow or hip of subject.
    Type: Application
    Filed: November 30, 2017
    Publication date: July 30, 2020
    Inventors: Satyen SANGHAVI, Vinayak KEDAGE
  • Publication number: 20200239847
    Abstract: The disclosure provides a method of preparing a pluripotent stem cell suitable for differentiating into a cardiomyocyte comprising (1) culturing at least one pluripotent stem cell on a low cell adhesion substrate to generate a dome-like colony; and (2) collecting a cell from the dome-like colony. The disclosure also provides a method of preparing a population of cardiomyocytes comprising inducing myocardial differentiation of a population of pluripotent stem cells prepared by the method described above.
    Type: Application
    Filed: October 17, 2018
    Publication date: July 30, 2020
    Applicant: Kyoto University
    Inventors: Li Liu, Leqian Yu, Junjun Li
  • Publication number: 20200239848
    Abstract: The present invention relates to in vitro methods of enriching populations of human pluripotent stem cells that are induced to differentiate to cardiomyocyte progenitor cells and cardiomyocyte cells. The cell populations can be enriched by isolating cells that express SIRPA. The invention also related to in vitro-enriched populations of cardiomyocyte cells and cardiomyocyte progenitor cells obtained from populations of pluripotent stem.
    Type: Application
    Filed: April 13, 2020
    Publication date: July 30, 2020
    Inventors: Gordon Keller, April M. Craft, Nicole C. Dubois
  • Publication number: 20200239849
    Abstract: A method for purifying and enriching mesenchymal stem cells (MSCs) simply and efficiently. Separation of cells expressing CD73 protein on the surface from fresh tissue isolated from a living body allows purification and enrichment of MSCs easily and efficiently. MSCs may be selectively isolated with a single antibody before culturing to establish a culture system of mesenchymal stem cells that enhances the engraftment efficiency in the transplanted site.
    Type: Application
    Filed: May 11, 2018
    Publication date: July 30, 2020
    Inventors: Chihiro AKAZAWA, Eriko Grace SUTO, Yo MABUCHI
  • Publication number: 20200239850
    Abstract: The present invention provides human bone-marrow cells enriched with functional mitochondria, methods for their production, and therapeutic methods utilizing such cells.
    Type: Application
    Filed: March 24, 2020
    Publication date: July 30, 2020
    Inventors: Natalie YIVGI-OHANA, Uriel HALAVEE
  • Publication number: 20200239851
    Abstract: Disclosed is a nanofiber-based long-term primary hepatocyte culture system and a culture method, wherein the primary hepatocyte culture system has an advantage that it can culture cells in three-dimensions in vitro to maintain the original physiological activity of low proliferative primary hepatocytes for a long time by co-culturing indirectly by separating primary hepatocytes and hepatic non-parenchymal cells with a support consisting of nanofibers therebetween without direct co-culture.
    Type: Application
    Filed: September 21, 2018
    Publication date: July 30, 2020
    Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Jong-Young KWAK, Min Gyu SONG, So Hee KIM, Min Ho CHOI
  • Publication number: 20200239852
    Abstract: A method of cell culture comprising providing cells in a cell culture medium to start a cell culture process, and, maintaining at least one metabolite selected from 3-(4-hydroxyphenyl)lactate, 4-hydroxyphenylpyruvate, phenyllactate, indolelactate, indolecarboxylic acid, homocysteine, 2-hydroxybutyric acid, isovalerate and formate below a concentration C1 in the cell culture medium, wherein C1 is 3 mM and/or (ii) maintaining at least one amino acid selected from phenylalanine, tyrosine, tryptophan, methionine, leucine, serine, threonine and glycine below a concentration C2 in the cell culture medium, wherein C2 is 2 mM.
    Type: Application
    Filed: December 20, 2019
    Publication date: July 30, 2020
    Applicant: Pfizer Inc.
    Inventors: Gregory Walter Hiller, Bhanu Chandra Mulukutla
  • Publication number: 20200239853
    Abstract: Provided are stem cells-induced Serotoli-like cells, methods of preparing the same, and uses thereof. Sertoli-like cells according to one embodiment can be differentiated from embryonic stem cells with excellent proliferative capacity, and thus, can be obtained in large quantities. Also, since the Sertoli-like cells secrete immunosuppressive substances and form immune privilege and induce anti-inflammatory functions, they can be used for development of the cell therapeutic agent.
    Type: Application
    Filed: March 6, 2020
    Publication date: July 30, 2020
    Applicant: CHA University Industry-Academic Cooperation Foundation
    Inventors: Dong Ryul LEE, Dong Won Seol
  • Publication number: 20200239854
    Abstract: Provided are a method capable of evaluating adherent cells under an environment similar to an in vivo environment by a culture method similar to a two-dimensional culture, and applications thereof. An adherent cell culture method uses, as a culture chamber (10), a chamber in which two or more culture spaces each having an equivalent diameter (D) that is 1 to 5 times the diameter of a desired spheroid and each having a height (H) that is 0.3 to 5 times the equivalent diameter are arranged and a surface of each of the culture spaces has a water contact angle of 45 degrees or less. Spheroids of adherent cells are cultured in the respective culture spaces (11) arranged in the culture chamber (10).
    Type: Application
    Filed: April 13, 2020
    Publication date: July 30, 2020
    Inventors: Satoru Ayano, Masaya Hosoda, Yoko Ejiri, Go Tazaki
  • Publication number: 20200239855
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Application
    Filed: October 28, 2019
    Publication date: July 30, 2020
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • Publication number: 20200239856
    Abstract: The present invention aims to provide a method for producing a cartilage tissue, which enables production of a cartilage tissue having an appropriate thickness, form, and mechanical strength, and a cartilage tissue produced by the method for producing a cartilage tissue. Provided is a method for producing a cartilage tissue including a step of seeding a collagenase-treated cartilage tissue piece in the form of a block 50 to 1,000 ?m on a side onto a porous substrate composed of a bioabsorbable material.
    Type: Application
    Filed: November 29, 2018
    Publication date: July 30, 2020
    Inventors: William J. LANDIS, Robin CHILDS, Narihiko HIRANO, Tomokazu FUKUDA
  • Publication number: 20200239857
    Abstract: Disclosed is a skin-on-a-chip, which more closely resembles real skin by simulating the repetition of contraction and relaxation due to stretching of skin cells, by embedding a permanent magnet in the skin-on-a-chip. The skin-on-a-chip includes a connector that causes a linear motion in the skin cells of the chip when driven by a linear drive device outside the chip, which provides forward and backward movement, to thereby simulate contraction and relaxation of skin.
    Type: Application
    Filed: December 29, 2017
    Publication date: July 30, 2020
    Inventors: Gun Yong SUNG, Ho Yeong LIM, Hyun Jeong SONG, Sungsu PARK
  • Publication number: 20200239858
    Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.
    Type: Application
    Filed: September 4, 2019
    Publication date: July 30, 2020
    Inventors: Harry E. Gruber, Douglas J. Jolly, Omar D. Perez, Christopher R. Logg
  • Publication number: 20200239859
    Abstract: The invention generally concerns the production of defective Adenovirus helper viruses for producing a recombinant adeno-associated virus (rAAV), wherein the Adenovirus helper virus contains at least one mutation selected from (a) an inactivating mutation in the transcription unit coding for the L4-100K protein; (b) an inactivating mutation in the transcription unit coding for the L1-52/55K protein; (c) an inactivating mutation in the transcription unit coding for the preterminal protein (pTP); (d) a mutation in the L4-100K protein in order to render it temperature-sensitive (ts); (e) a mutation in the hexon protein in order to render it temperature-sensitive (ts); and/or (f) a mutation in the L4-00K protein and a mutation in the hexon protein in order to render it temperature-sensitive (ts).
    Type: Application
    Filed: October 12, 2018
    Publication date: July 30, 2020
    Inventors: Markus HÖRER, Stefan KOCHANEK, Caroline HAUSER, Alexandra KRÜGER-HAAG
  • Publication number: 20200239860
    Abstract: Disclosed herein are methods and systems for rapid detection of microorganisms such as Listeria spp. in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as Listeria-specific bacteriophage, allows detection of a specific microorganism, such as Listeria spp. and an indicator signal may be amplified to optimize assay sensitivity.
    Type: Application
    Filed: January 29, 2020
    Publication date: July 30, 2020
    Inventors: Stephen Erickson, Jose S. Gil, Minh Mindy Bao Nguyen, Dwight L. Anderson
  • Publication number: 20200239861
    Abstract: A method of preparing isolated microsomes comprising an irreversibly inhibited cytochrome P450 (CYP450). Isolated microsomes are characterized in that a cytochrome P450 thereof is irreversibly inhibited by a non-reversible inhibitor. The isolated microsomes according to the invention may be used in a method of phenotyping enzymatic reactions of a drug candidate.
    Type: Application
    Filed: April 17, 2020
    Publication date: July 30, 2020
    Inventors: Fabrice CARADEC, Yannick Parmentier, Corinne Pothier
  • Publication number: 20200239862
    Abstract: The present invention relates to a pharmaceutical composition for prevention and treatment of heart failure. Specifically, the present invention relates to a gene construct comprising a polynucleotide coding for SERCA2a protein or a fragment thereof and a polynucleotide coding for CCN5 protein or a fragment thereof, and a pharmaceutical composition comprising the same construct as an effective ingredient for preventing or treating heart failure. A pharmaceutical composition for prevention and treatment of heart failure according to the present invention is used in a method for co-expression of SERCA2a protein and CCN5 protein.
    Type: Application
    Filed: September 28, 2018
    Publication date: July 30, 2020
    Applicant: BETHPHAGEN INC.
    Inventors: Tae Hwan KWAK, Woo Jin PARK
  • Publication number: 20200239863
    Abstract: Cas9 polypeptides which target RNA and methods of using them are provided
    Type: Application
    Filed: February 19, 2020
    Publication date: July 30, 2020
    Inventors: Eugene Yeo, David A. Nelles, Mark Fang, Ranjan Batra
  • Publication number: 20200239864
    Abstract: The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within an open reading frame (ORF) of the genome of at least two genotypes of the Hepatitis B virus (HBV). The present invention also encompasses methods of using such engineered meganucleases in a pharmaceutical composition and in methods for treating or reducing the symptoms of a HBV infection, or treating hepatocellular carcinoma (HCC). Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating HBV infections or HCC.
    Type: Application
    Filed: April 17, 2020
    Publication date: July 30, 2020
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith
  • Publication number: 20200239865
    Abstract: The present invention relates to the technical field of protein engineering, and, in particular, to a xylanase mutant with improved heat tolerance. The present invention artificially introduces two or three unnatural disulfide bridges into xylanase by site-directed mutagenesis and obtains the mutants XynA1 and XynA2 with improved heat tolerance, especially the mutant XynA2 into which three disulfide bridges are introduced, achieving residual enzyme activity of 75% after treatment at 80° C. for 5 min, 72% higher than the residual enzyme activity of the mutant XynA1. The present invention further obtains, by screening, three mutation sites Q51N, H143K, and Q161F that can significantly increase the heat tolerance of mutants, and introduction of the mutation sites into the XynA1 and XynA2 xylanases, whether at a single point or a combination of two points or a combination of three points, can effectively improve the heat tolerance of the mutants.
    Type: Application
    Filed: April 19, 2018
    Publication date: July 30, 2020
    Applicant: QINGDAO VLAND BIOTECH GROUP CO., LTD
    Inventors: Xiuxiu WU, Chao SHAO, Yijun HUANG
  • Publication number: 20200239866
    Abstract: Engineered fusion proteins comprising a self-excising degron for controlling protein production are disclosed. In particular, the inventors have constructed fusion proteins comprising a degron connected to a protein of interest through a cleavable linker comprising a hepatitis C virus (HCV) protease site. The degron can be removed from the protein of interest by a cis-encoded HCV protease such that the protein of interest can be produced with minimal structural modification. Clinically available HCV protease inhibitors can be used to block protease cleavage such that the degron is retained after inhibitor addition on subsequently synthesized protein copies. The degron when attached causes rapid degradation of the linked protein. Such fusions of a degron to a protein of interest will be especially useful when control over protein production with minimal structural modification is desired.
    Type: Application
    Filed: February 3, 2020
    Publication date: July 30, 2020
    Inventors: Michael Z. LIN, Hokyung CHUNG, Conor JACOBS
  • Publication number: 20200239867
    Abstract: Variant guinea pig L-asparaginases which are truncated and humanized are described as are fusion proteins containing the L-asparaginase and use of the L-asparaginases in the treatment of cancers such as acute lymphoblastic leukemia and acute myeloid leukemia.
    Type: Application
    Filed: August 10, 2018
    Publication date: July 30, 2020
    Inventors: Arnon Lavie, Hien-An Nguyen, Amanda Schalk
  • Publication number: 20200239868
    Abstract: The present disclosure relates to the generation of an activated platelet product in which one or more of the presence or absence of clots, the timing of clot formation (if present), and/or the mechanical strength of clots (if present) is controlled by the presence or concentration of calcium ions during the activation process. In certain embodiments, the calcium ion concentration is controlled in the presence of pulsed electric fields or a chemical activator (e.g., thrombin) as part of the activation process.
    Type: Application
    Filed: April 16, 2020
    Publication date: July 30, 2020
    Inventors: Vasile Bogdan Neculaes, Andrew Soliz Torres, Steve Lambert Klopman
  • Publication number: 20200239869
    Abstract: Aspects of the disclosure relate to liquid chromatography (e.g., HPLC) methods which enable high resolution separations of polynucleotides of various lengths, sequences, and/or base compositions in a highly tunable manner. In some embodiments, the disclosure describes liquid chromatographic methods for separating a nucleic acid (e.g., a polyadenylated nucleic acid, such as an mRNA) from a complex mixture by using multiple ion pairing agents in the same mobile phase system. Accordingly, in some embodiments methods described by the disclosure are useful for assessing the quality of pharmaceutical preparations comprising nucleic acids.
    Type: Application
    Filed: August 17, 2018
    Publication date: July 30, 2020
    Applicant: ModernaTX, Inc.
    Inventors: William Issa, Meredith Packer
  • Publication number: 20200239870
    Abstract: The present invention relates to the field of nucleic acid purification. In particular, it relates to methods and tools for purifying nucleic acids in a sample; which are compatible with high-throughput sequencing and diagnosis. The inventors have shown that nucleic acid binding proteins recruited to polymerized tubulin (i.e. microtubules) could, subsequently, be isolated from cell lysates. Surprisingly, it has now been found that the amount of recovered nucleic acid found in these microtubule pellets increases dramatically in the presence of nucleic acid-trapping proteins comprising a nucleic acid-binding moiety and a polymerized tubulin-binding moiety, by comparison to proteins devoid of the nucleic acid-binding moiety; and that the recovery of the purified nucleic acids was itself particularly efficient. This purification method is particularly amenable to high-throughput sequencing and/or in the context of a diagnosis method for identifying or comparing the amount of nucleic acids in a set of samples.
    Type: Application
    Filed: July 27, 2018
    Publication date: July 30, 2020
    Inventors: David PASTRE, Bénédicte DESFORGES, Alexandre MAUCUER
  • Publication number: 20200239871
    Abstract: The present invention relates to a method for selectively depleting animal nucleic acids from non-animal nucleic acids in a sample, which comprises animal cells and at least one further type of cells, selected from microbial cells and plant cells or a combination thereof, to a lysis solution A to be used in and to a kit to carry out said method as well as to the use of a particular silica membrane as both, a filtration matrix for separating essentially intact microbial and/or plant cells from lysed animal cells and an adsorption matrix for nucleic acids, in particular in a method according to the present invention.
    Type: Application
    Filed: April 14, 2020
    Publication date: July 30, 2020
    Inventors: Johann KUBICEK, Thorsten SINGER, Antje-Katrin SANDER, Eva HÄNSSLER, Dominic O'NEIL
  • Publication number: 20200239872
    Abstract: Provided herein is an antigen display library for detecting antibodies produced by an individual; and methods of using the antigen display library to generate an antibody signature, the method comprising contacting a biological sample containing antibodies from an individual with the antigen display library, isolating phage clones displaying antigenic epitopes recognized by antibody in the sample, and identifying the antigenic epitopes that were recognized by antibody in the sample. Also provided are kits for generating an antibody signature comprising the antigen display library, a substrate for isolating phage clones bound by antibody, and may further comprise reagents useful for generating the antibody signature.
    Type: Application
    Filed: March 13, 2018
    Publication date: July 30, 2020
    Applicant: Duke University
    Inventors: Thomas F. TEDDER, Evgueni KOUNTIKOV
  • Publication number: 20200239873
    Abstract: The present disclosure provides a HTP microbial genomic engineering platform that is computationally driven and integrates molecular biology, automation, and advanced machine learning protocols. This integrative platform utilizes a suite of HTP molecular tool sets to create HTP genetic design libraries, which are derived from, inter alia, scientific insight and iterative pattern recognition. The HTP genomic engineering platform described herein is microbial strain host agnostic and therefore can be implemented across taxa. Furthermore, the disclosed platform can be implemented to modulate or improve any microbial host parameter of interest.
    Type: Application
    Filed: April 2, 2020
    Publication date: July 30, 2020
    Inventors: Zach SERBER, Erik Jedediah Dean, Shawn Manchester, Katherine Gora, Michael Flashman, Erin Shellman, Aaron Kimball, Shawn Szyjka, Barbara Frewen, Thomas Treynor, Kenneth S. Bruno
  • Publication number: 20200239874
    Abstract: The present disclosure provides methods of processing or analyzing a sample. A method for processing a sample may comprise hybridizing a probe molecule to a target region of a nucleic acid molecule (e.g., a ribonucleic acid (RNA) molecule), barcoding the probe-nucleic acid molecule complex, and performing extension, denaturation, and amplification processes. A method for processing a sample may comprise hybridizing first and second probes to adjacent or non-adjacent target regions of a nucleic acid molecule (e.g., an RNA molecule), linking the first and second probes to provide a probe-linked nucleic acid molecule, and barcoding the probe-linked nucleic acid molecule. One or more processes of the methods described herein may be performed within a partition, such as a droplet or well. One or more processes of the methods described herein may be performed on a cell, such as a permeabilized cell.
    Type: Application
    Filed: August 28, 2019
    Publication date: July 30, 2020
    Inventors: Tarjei Sigurd Mikkelsen, Eswar Prasad Ramachandran Iyer, Andrew Kohlway, Luigi Jhon Alvarado Martinez, Katherine Pfeiffer, Andrew D. Price
  • Publication number: 20200239875
    Abstract: The invention provides methods for controlling the density of different molecular species on the surface of a solid support. A first mixture of different molecular species is attached to a solid support under conditions to attach each species at a desired density, thereby producing a derivatized support having attached capture molecules. The derivatized support is treated with a second mixture of different molecular species, wherein different molecular species in the second mixture bind specifically to the different capture molecules attached to the solid support. One or more of the capture molecules can be reversibly modified such that the capture molecules have a different activity before and after the second mixture of molecular species are attached. In particular embodiments, the different molecular species are nucleic acids that are reversibly modified to have different activity in an amplification reaction.
    Type: Application
    Filed: February 10, 2020
    Publication date: July 30, 2020
    Inventors: Andrea Sabot, Roberto Rigatti, Min-Jui Richard Shen
  • Publication number: 20200239876
    Abstract: The present invention provides new methods and kits to improve the efficiency of ligation reactions, in particular in molecular biology applications, such as the next generation sequencing (NGS) library construction methods. In next-generation sequencing methods, the ligation step is critical in adding sequencing platform-specific adapters to the DNA fragments that are to be sequenced. Said improvement is achieved by the addition of single- or double-stranded DNA-binding proteins in the ligation step.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 30, 2020
    Inventors: Katja Heitz, Nan Fang
  • Publication number: 20200239877
    Abstract: The invention provides particle compositions having applications in nucleic acid analysis. Nucleic acid polymer particles of the invention allow polynucleotides to be attached throughout their volumes for higher loading capacities than those achievable solely with surface attachment. In one aspect, nucleic acid polymer particles of the invention comprise polyacrylamide particles with uniform size distributions having low coefficients of variations, which result in reduced particle-to-particle variation in analytical assays. Such particle compositions are used in various amplification reactions to make amplicon libraries from nucleic acid fragment libraries.
    Type: Application
    Filed: April 6, 2020
    Publication date: July 30, 2020
    Inventors: Wolfgang HINZ, John LEAMON, David LIGHT, Jonathan M. ROTHBERG
  • Publication number: 20200239878
    Abstract: Described herein are methods and compositions that provide highly efficient nucleic acid amplification. In some embodiments, this allows a 3-fold or greater increase of amplification product for each amplification cycle and therefore increased sensitivity and speed over conventional PCR. Modified bases can be employed in primers to provide this base-3 or greater amplification with satisfactory PCR cycle times, which are improved, as compared to those observed in the absence of modified bases.
    Type: Application
    Filed: October 29, 2019
    Publication date: July 30, 2020
    Applicant: Cepheid
    Inventor: Russell Higuchi
  • Publication number: 20200239879
    Abstract: Compositions and methods for conditionally regulating activities of CRISPR-Cas systems. In some embodiments, the methods comprise providing an inactive guide RNA comprising a regulatory domain bound by a lock nucleic acid different from the guide RNA; and displacing the lock nuclei acid from the regulatory domain by a trigger nucleic acid, thereby activating the guide RNA, wherein the activated guide RNA forms a complex with a Cas enzyme.
    Type: Application
    Filed: January 29, 2020
    Publication date: July 30, 2020
    Inventors: Amit Choudhary, Kurt Cox, Hari Subramanian, Elisa Franco
  • Publication number: 20200239880
    Abstract: Methods of inhibiting influenza A virus in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a PSL2 motif with an effective amount of an agent that specifically binds the PSL2 motif to inhibit the influenza A virus. Also provided are methods of treating or preventing influenza A virus infection in a subject. Also provided are methods for screening a candidate agent for the ability to inhibit influenza A virus in a cell, the method comprising: contacting a sample with a candidate agent; and determining whether the candidate agent specifically binds to the PSL2 motif of vRNA. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a PB2 vRNA region that find use in the subject methods.
    Type: Application
    Filed: February 14, 2020
    Publication date: July 30, 2020
    Inventors: Jeffrey S. Glenn, Rachel Hagey Saluti, Edward A. Pham
  • Publication number: 20200239881
    Abstract: The present invention provides morpholino modified oligomeric compounds having at least one monomer subunit having Formula III, compounds having Formula I useful for making certain of the morpholino modified oligomeric compounds and methods of using the oligomeric compounds. In certain embodiments, the oligomeric compounds provided herein provide for an improved toxicity profile. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount of activity or expression of the target nucleic acid in a cell.
    Type: Application
    Filed: March 9, 2018
    Publication date: July 30, 2020
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Michael Oestergaard, Punit P. Seth